COMBINATION ANTIFUNGAL THERAPY WITH MICAFUNGIN (MICA) AND AMPHOTERICIN B DESOXYCHOLATE (AMB-D) PROLONGS SURVIVAL IN THE P47PHOX-DEFICIENT MOUSE MODEL OF CHRONIC GRANULOMATOUS DISEASE (CGD) WITH EXPERIMENTAL PULMONARY ASPERGILLOSIS

Dennis C1, Failing C1, Greco WR1, Slocum H1, Bernacki R1, Pera P1, Lewis R2, Holland SM3, Walsh TJ3, Segal BH1

Author address: 

1Roswell Park Cancer Institute, Buffalo, USA 2MD Anderson Cancer Center, Houston, USA 3 National Institutes of Health, Bethesda, USA

Abstract: 

Background: CGD is an inherited disorder of the NADPH oxidase characterized by recurrent life threatening bacterial and fungal infections and excessive inflammatory responses. We evaluated combination antifungal therapy in CGD mice with experimental aspergillosis. Methods: Survival: CGD mice were challenged with intratracheal A. fumigatus conidia (1.25 x 10E4 CFU/mouse). Mice (n=10-12 per treatment group pooled from 2 experiments) received one of the following regimens daily from day 0 to 4 after challenge: 1) IV vehicle + IP vehicle; 2) IV Mica (10 mg/kg) + IP vehicle; 3) IV vehicle + IP Amb-d (1 mg/kg); or 4) IV Mica (10 mg/kg) + IP Amb-d B (1 mg/kg). Histopathology: In separate experiments, CGD mice received a sub-lethal challenge of A. fumigatus (1.25 x 10E3 CFU/mouse), and antifungal therapy was administered (n=3-4 mice per treatment group) daily on days 7-11 after challenge. Mice were sacrificed and lungs harvested for pathology on day 14. Results: Survival: Mice receiving combination Mica + Amb-d had significantly longer survival than any other group (log rank, p
2004

abstract No: 

none

Full conference title: 

14th Annual Focus on Fungal Infections
    • FFI 2004 (14th)